BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Compendia Bioscience Release: Oncomine Contributes to Integrative Genomic Analysis of Lethal Castration-Resistant Prostate Cancer


5/22/2012 10:19:13 AM

ANN ARBOR, Mich., May 21, 2012 /PRNewswire-USNewswire/ -- A study by researchers from the University of Michigan, Yale School of Public Health, Brown University and Compendia Bioscience was published in Nature. The study is notable for its comprehensive genomic profiling of patients with pre-treated lethal metastatic disease, providing insights into mechanisms of resistance.

The study identified a diverse series of likely driving mutations and copy number alterations in both known and novel genes. Oncomine streamlined analysis of genome alterations and provided a platform for rapid validation across previously published studies.

"The Oncomine tool set was developed to mine the global collection of cancer genomic data - our most recent advances focusing on mutation and copy number analysis. It is always rewarding to see our platform contributing to scientific discovery," said Dr. Daniel Rhodes, CEO of Compendia Bioscience.

Integrated analysis of copy number and mutation data identified loss of CHD1, a chromatin-modifying enzyme, as a key genetic event in ETS-negative prostate cancer. With Oncomine, the team was able to rapidly validate this observation across 13 independent, previously published patient cohorts.

"Oncomine continues to be my go-to reference database to analyze and validate cancer genomic findings," said Dr. Scott Tomlins, senior author of the study. "The latest advances in mutation and copy number analysis are quite powerful and the ability to quickly and easily compare multiple data sets is unmatched."

About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to curing cancers through the application of genomic data by providing researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. Visit www.compendiabio.com for more information.

About Oncomine
Oncomine combines a rapidly growing compendium of 62,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. Visit www.oncomine.com for more information.

SOURCE Compendia Bioscience, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES